Purple Biotech Ltd.(PPBT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PPBT Purple Biotech Ltd.

Pre-Mkt 03-23 07:10:56 EDT

3.98

+0.19

+5.05%

盘前4.00

+0.10+2.56%

07:01 EDT

High4.00	Low3.73	Vol9.82K
Open3.73	D1 Closing3.79	Amplitude7.13%
Mkt Cap3.70M	Tradable Cap3.33M	Total Shares929.50K
T/O38.15K	T/O Rate1.18%	Tradable Shares835.82K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PPBT","market":"US","secType":"STK","nameCN":"Purple Biotech Ltd.","latestPrice":3.98,"timestamp":1774036800000,"preClose":3.7888,"halted":0,"volume":9822,"hourTrading":{"tag":"盘前","latestPrice":4,"preClose":3.9,"latestTime":"07:01 EDT","volume":115,"amount":460,"timestamp":1774263715330,"change":0.1,"changeRate":0.025641,"amplitude":0},"delay":0,"changeRate":0.05046452702702697,"floatShares":835820,"shares":929500,"eps":-54.964,"marketStatus":"Pre-Mkt","change":0.1912,"latestTime":"03-23 07:10:56 EDT","open":3.73,"high":4,"low":3.73,"amount":38150.5623078,"amplitude":0.071263,"askPrice":4.88,"askSize":100,"bidPrice":3.67,"bidSize":117,"shortable":3,"etf":0,"ttmEps":-54.964,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774272600000},"marketStatusCode":1,"adr":0,"adrRate":200,"listingDate":1447995600000,"exchange":"NASDAQ","adjPreClose":3.9,"preHourTrading":{"tag":"盘前","latestPrice":4,"preClose":3.9,"latestTime":"07:01 EDT","volume":115,"amount":460,"timestamp":1774263715330,"change":0.1,"changeRate":0.025641,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.98,"preClose":3.98,"latestTime":"19:54 EDT","volume":32,"amount":124.66,"timestamp":1774050844600,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8812768946823752,"impliedVol":2.8623,"impliedVolPercentile":0.9839},"requestUrl":"/m/hq/s/PPBT","defaultTab":"news","newsList":[{"id":"2620731133","title":"Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620731133","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620731133?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:30","pubTimestamp":1774013431,"startTime":"0","endTime":"0","summary":"WSW, NY, March 20th, 2026, FinanceWire Cancer immunotherapy has already had its first revolution. Checkpoint inhibitors changed the treatment lands...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/purple-biotech-is-building-what-could-be-the-next-generation-of-cancer-immunotherapy-nasdaq-ppbt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/purple-biotech-is-building-what-could-be-the-next-generation-of-cancer-immunotherapy-nasdaq-ppbt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQY","BK4007","USJW.SI",".IXIC","GPIQ","QQQE","TSYW.SI","BK4585","USAW.SI","MNQmain","TQQQ","PPBT","SQQQ","QID","QQQJ","QLD","XBI","BK4581","NVIW.SI","PSQ","NQmain","BK4588","JEPQ","QYLG"],"gpt_icon":0},{"id":"2620207710","title":"Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2620207710","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620207710?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:01","pubTimestamp":1773986474,"startTime":"0","endTime":"0","summary":"Purple Biotech Ltd. (PPBT) has disclosed a new risk, in the Trade Secrets category. The analyst notes that Purple Biotech Ltd. faces meaningful exp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/patent-cliff-risk-how-expiring-protections-threaten-purple-biotechs-future-exclusivity-and-returns?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/patent-cliff-risk-how-expiring-protections-threaten-purple-biotechs-future-exclusivity-and-returns?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","XBI","BK4581","PPBT","BK4585"],"gpt_icon":0},{"id":"2620297304","title":"Purple Biotech regains compliance with Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2620297304","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620297304?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:31","pubTimestamp":1773747097,"startTime":"0","endTime":"0","summary":"Purple Biotech (PPBT) received confirmation from the Listing Qualifications Department of Nasdaq that the company had regained compliance with the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/purple-biotech-regains-compliance-with-nasdaq-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/purple-biotech-regains-compliance-with-nasdaq-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4588","NQmain","PPBT","BK4581","BK4585","BK4007"],"gpt_icon":0},{"id":"2619710194","title":"Israel's Purple Biotech Q4 net loss widens on impairment charge","url":"https://stock-news.laohu8.com/highlight/detail?id=2619710194","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619710194?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:10","pubTimestamp":1773403815,"startTime":"0","endTime":"0","summary":"Israel's Purple Biotech Q4 net loss widens on impairment chargeOverviewIsrael immunotherapy developer's Q4 net loss widened on a $20.5 mln impairment chargeAdjusted operating loss for Q4 increased due","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL1N4010HR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PPBT"],"gpt_icon":0},{"id":"2619194161","title":"Press Release: Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194161","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619194161?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:00","pubTimestamp":1773403200,"startTime":"0","endTime":"0","summary":"Focus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific antibody, IM1305, named as development candidate, targeting TROP2. Achieved toxicology and manufacturing milestones for IM1240, demonstrating an expanded therapeutic window and commercially viable yield. Total Cash Position of $9.5 million as of December 31, 2025, expected to provide runway into 2027. \"In 2025, we focused on the CAPTN-3 platform and the value it can generate for patients and shareholders, naming a second tri-specific antibody from the platform, IM1305, and strengthening the preclinical data package for the first tri-specific antibody, IM1240. In addition, the capital we raised in 2025 is expected to provide runway into 2027, covering preparations for IM1240 Phase 1 study initiation,\" said Gil Efron, Purple Biotech CEO. \"During the past year, we made efforts to partner both CM24 and NT219 and, as previously report","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Press Release: Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","PPBT","BK4581","XBI","BK4007"],"gpt_icon":0},{"id":"2619191135","title":"Purple Biotech Ltd  expected to post a loss of $3.40 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619191135","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619191135?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:39","pubTimestamp":1773401946,"startTime":"0","endTime":"0","summary":"Purple Biotech Ltd  expected to post a loss of $3.40 a share - Earnings Preview Purple Biotech Ltd PPBT.OQ, PPBT.O is expected to  show no change in quarterly revenue when it reports  results on March","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N4010YS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PPBT"],"gpt_icon":0},{"id":"2614969218","title":"NASDAQ TRADE HALT CONTINUES  HALT NEWS PENDING AT 07:59 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2614969218","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614969218?lang=en_us&edition=fundamental","pubTime":"2026-02-28 08:59","pubTimestamp":1772240384,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  HALT NEWS PENDING AT 07:59 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260228:nAQN2LO82B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPBT","BK4007"],"gpt_icon":0},{"id":"2614916896","title":"Purple Biotech trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2614916896","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614916896?lang=en_us&edition=fundamental","pubTime":"2026-02-28 08:50","pubTimestamp":1772239834,"startTime":"0","endTime":"0","summary":"19:50 EST Purple Biotech (PPBT) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/purple-biotech-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/purple-biotech-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4007","LABU","PPBT"],"gpt_icon":0},{"id":"2614752858","title":"Purple Biotech Ltd  expected to post a loss of 34 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2614752858","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614752858?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:18","pubTimestamp":1772194693,"startTime":"0","endTime":"0","summary":"Purple Biotech Ltd  expected to post a loss of34cents a share - Earnings Preview Purple Biotech Ltd PPBT.OQ, PPBT.O is expected to  show no change in quarterly revenue when it reports  results on Marc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL8N3ZN1CE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPBT","BK4007"],"gpt_icon":0},{"id":"2584215990","title":"Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (TEVA) and Purple Biotech (PPBT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584215990","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584215990?lang=en_us&edition=fundamental","pubTime":"2025-11-19 14:40","pubTimestamp":1763534450,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teva Pharmaceutical (TEVA – Research Report) and Purple Biotech (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-teva-pharmaceutical-teva-and-purple-biotech-ppbt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-teva-pharmaceutical-teva-and-purple-biotech-ppbt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4559","BK4588","XLV","LU0128526141.USD","BK4137","XBI","BK4557","BK4007","BK4566","BK4596","LU1983299246.USD","TEVA","BK4585","LABU","BK4584","PPBT","LU0029874061.USD","BK4581","HCSG"],"gpt_icon":0},{"id":"2583062015","title":"Purple Biotech Q3 net loss widens to $1.3 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2583062015","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583062015?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:08","pubTimestamp":1763125707,"startTime":"0","endTime":"0","summary":"Purple Biotech Q3 net loss widens to $1.3 mlnOverviewPurple Biotech Q3 net loss $1.3 mln, up from $0.7 mln last yearOperating loss decreased due to reduced CM24 Phase 2 study expensesCompany has $10.5","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ0IW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPBT","BK4007"],"gpt_icon":0},{"id":"2580841697","title":"ADRs End Lower; Purple Biotech Ltd. Declines 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580841697","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580841697?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:30","pubTimestamp":1761942600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed lower on Friday, as the S&P/BNY Mellon index of American depositary receipts fell 0.3% to 230.25.The European index declined 0.1% to 199.87. The Asian index fell 0.6% to 314.05. The Latin American index increased 0.5% to 227.15, while the emerging-markets index declined 0.6% to 527.38.Purple Biotech Ltd., based in Israel, posted the largest decline, tumbling 16% to 79 cents, followed by shares of China's VisionSys AI Inc., which tumbled 14% to $2.16. Shares of Italy-based Genenta Science S.p.A. tumbled 10% to $2.57.Singapore's AMTD Digital Inc. was the biggest leader during the session, rocketing 75% to $2.95, and China-based LexinFintech Holdings Ltd. rocketed 25% to $4.82. AMTD IDEA Group, which is based in Hong Kong, rounded out the top three leaders on Friday, with shares soaring 24% to $1.29.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPBT","BK4007"],"gpt_icon":0},{"id":"2579613601","title":"ADRs End Flat; Purple Biotech Ltd. Climbs 82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579613601","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579613601?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:30","pubTimestamp":1761769800,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed flat on Wednesday, as the S&P/BNY Mellon index of American depositary receipts held steady at 232.40.The European index dropped 0.3% to 200.62. The Asian index added 0.2% to 319.21. The Latin American index rose 1.0% to 226.84, while the emerging-markets index increased 0.8% to 537.02.Israel's Purple Biotech Ltd. was the biggest leader during the session, soaring 82% to $1.06, and Switzerland-based WISeKey International Holding Ltd. soared 28% to $15.92. Genenta Science S.p.A., which is based in Italy, rounded out the top three leaders on Wednesday, with shares soaring 25% to $3.01.Quhuo Ltd., based in China, posted the largest decline, plummeting 84% to $1.26, followed by shares of France's Inventiva S.A., which cratered 21% to $4.16. Shares of Japan-based MEDIROM Healthcare Technologies Inc. plummeted 21% to $2.07.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPBT","BK4007"],"gpt_icon":0},{"id":"2579390479","title":"Dow Surges 250 Points; Verizon Posts Mixed Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2579390479","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579390479?lang=en_us&edition=fundamental","pubTime":"2025-10-29 21:57","pubTimestamp":1761746276,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/10/48494717/dow-surges-250-points-verizon-posts-mixed-q3-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADNH","LU0985481810.HKD","ADN","LU0321505868.SGD","USJW.SI","BK4550","BK4588","LU2125909759.SGD","LU1066051811.HKD","LU0868494617.USD","LU1162221912.USD","LRN","QID",".IXIC","QLD","TQQQ","BK4097","LU2384288077.EUR","LU0321505439.SGD","LU2125909916.SGD","PSQ","LU0306807586.USD","BK4007","LU2065731478.USD","LU0225771236.USD","TSYW.SI","LU1366192091.USD","VRNS","IE0009354923.USD","SQQQ","IE00BSNM7G36.USD","LU1923622291.USD","PPBT","LU0225284248.USD","BK4559","LU0868494708.USD","PCOM","NVIW.SI","USAW.SI","LU0306806265.USD","VZ","LU2286300806.USD","LU1621768206.USD","BK4581","CMBM","MNQmain","FGL","LU0942090050.USD","NQmain","BK4129"],"gpt_icon":1},{"id":"2577137893","title":"Purple Biotech receives noncompliance notification from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2577137893","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577137893?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:05","pubTimestamp":1760990722,"startTime":"0","endTime":"0","summary":"Purple Biotech (PPBT) announced that it received a letter from the listings qualifications department of Nasdaq notifying the company that it is no...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/purple-biotech-receives-noncompliance-notification-from-nasdaq-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/purple-biotech-receives-noncompliance-notification-from-nasdaq-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQQ","QID","USJW.SI","MNQmain","PPBT","QLD","SQQQ","NVIW.SI","PSQ","USAW.SI","NQmain",".IXIC","BK4007","TSYW.SI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.purple-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0293},{"period":"1month","weight":-0.309},{"period":"3month","weight":-0.4375},{"period":"6month","weight":-0.3173},{"period":"1year","weight":-0.8558},{"period":"ytd","weight":-0.3947}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.004044},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.007421},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.022828},{"month":4,"riseRate":0.5,"avgChangeRate":0.001785},{"month":5,"riseRate":0.5,"avgChangeRate":0.095894},{"month":6,"riseRate":0.2,"avgChangeRate":-0.028974},{"month":7,"riseRate":0.3,"avgChangeRate":-0.037583},{"month":8,"riseRate":0.5,"avgChangeRate":0.443934},{"month":9,"riseRate":0.3,"avgChangeRate":-0.135378},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014741},{"month":11,"riseRate":0.3,"avgChangeRate":-0.035023},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.064801}],"exchange":"NASDAQ","name":"Purple Biotech Ltd.","nameEN":"Purple Biotech Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Purple Biotech Ltd.(PPBT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Purple Biotech Ltd.(PPBT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Purple Biotech Ltd.,PPBT,Purple Biotech Ltd.股票,Purple Biotech Ltd.股票老虎,Purple Biotech Ltd.股票老虎国际,Purple Biotech Ltd.行情,Purple Biotech Ltd.股票行情,Purple Biotech Ltd.股价,Purple Biotech Ltd.股市,Purple Biotech Ltd.股票价格,Purple Biotech Ltd.股票交易,Purple Biotech Ltd.股票购买,Purple Biotech Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Purple Biotech Ltd.(PPBT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Purple Biotech Ltd.(PPBT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction